Related Experiment Video
Updated: Jan 22, 2026

Determination of Total Lipid and Lipid Classes in Marine Samples
Published on: December 11, 2021
(5R)-5-hydroxytriptolide ameliorates liver lipid accumulation by suppressing lipid synthesis and promoting lipid
Yunxia Dong1, Henglei Lu2, Qiang Li3
1Center for Drug Safety Evaluation and Research, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 501 Haike Road, Shanghai 201203, China; University of Chinese Academy of Sciences, No.19A Yuquan Road, Beijing 100049, China.
Aims:
(5R)-5-hydroxytriptolide (LLDT-8) is a triptolide analog with excellent capability against cancers, cerebral ischemic injury and rheumatoid arthritis. Here, we discovered its hepatoprotective effects in a mouse model of non-alcoholic fatty liver disease (NAFLD) by ameliorating liver lipid accumulation.
Main Methods:
Male C57BL/6J mice were fed with a high-fat/high-fructose (HFHFr) diet for 29 weeks to induce the pathological phenomena of NAFLD. Then the mice were treated with LLDT-8 (0.5mg/kg and 1mg/kg) or Vehicle for 8 weeks. Finally, the serum biochemical indexes, liver histological features, fatty acids (FAs) profile and related gene expression in liver were detected to investigate the effect of LLDT-8 on lipid accumulation and its possible mechanism.
Key Findings:
LLDT-8 treatment significantly inhibited hepatic injury featured by the decrease of serum alanine aminotransferase (ALT) and aspartate transaminase (AST), the lessening of hepatic ballooning and macrovesicular steatosis. Moreover, LLDT-8 could downregulate the expression of stearoyl-CoA desaturase 1 (SCD1), which further led to the lower ratios of C16:1/C16:0 and C18:1/C18:0 and thus inhibited lipid synthesis. LLDT-8 treatment also could upregulate liver peroxisome proliferator-activated receptor α (PPARα), carnitine palmitoyltransferase 1a (Cpt1a), peroxisomal acyl-CoA oxidase 1 (Acox1), long-chain acyl-CoA dehydrogenase (Acadl) and medium-chain acyl-CoA dehydrogenase (Acadm) expression levels involved in fatty acids oxidation (FAO) and markedly promoted lipolysis.
Significance:
Our results provide a novel application of LLDT-8 in improving NAFLD.
Insights
The triptolide analog (5R)-5-hydroxytriptolide (LLDT-8) demonstrates hepatoprotective effects by reducing liver lipid accumulation in a non-alcoholic fatty liver disease (NAFLD) mouse model. LLDT-8 improves liver injury and promotes fatty acid oxidation, offering a novel therapeutic strategy for NAFLD.
Area of Science:
- Pharmacology
- Hepatology
- Metabolic Diseases
Background:
- Non-alcoholic fatty liver disease (NAFLD) is a growing global health concern characterized by excessive lipid accumulation in the liver.
- Current therapeutic options for NAFLD are limited, necessitating the exploration of novel treatment strategies.
- (5R)-5-hydroxytriptolide (LLDT-8), a triptolide analog, has shown potential in treating various conditions, including cancer and inflammatory diseases.
Purpose of the Study:
- To investigate the potential hepatoprotective effects of LLDT-8 in a mouse model of NAFLD.
- To elucidate the mechanisms underlying LLDT-8's action on liver lipid metabolism.
Main Methods:
- Male C57BL/6J mice were induced with NAFLD using a high-fat/high-fructose diet for 29 weeks.
- Mice were subsequently treated with LLDT-8 (0.5mg/kg and 1mg/kg) or vehicle for 8 weeks.
- Serum biochemical indexes, liver histology, fatty acid profiles, and gene expression related to lipid metabolism were analyzed.
Main Results:
- LLDT-8 treatment significantly reduced liver injury, indicated by decreased serum ALT and AST levels and improved hepatic steatosis.
- LLDT-8 downregulated stearoyl-CoA desaturase 1 (SCD1) expression, inhibiting lipid synthesis.
- LLDT-8 upregulated key genes involved in fatty acid oxidation (PPARα, Cpt1a, Acox1, Acadl, Acadm) and promoted lipolysis.
Conclusions:
- LLDT-8 exhibits significant hepatoprotective effects in a NAFLD mouse model.
- LLDT-8 ameliorates liver lipid accumulation by modulating lipid synthesis and enhancing fatty acid oxidation.
- LLDT-8 represents a promising therapeutic agent for the management of NAFLD.
Related Concept Videos
What are Lipids?
What are Lipids?
Non-Polar and Hydrophobic Characteristics of Lipids
Lipids are a structurally and functionally diverse group of hydrocarbons—compounds consisting of carbon and hydrogen atoms. The carbon-carbon and...
Lipid Digestion
Structure of Lipids
Lipid Catabolism
Lipids as Anchors
The carboxy-terminal of most of the prenylated proteins, such as Ras proteins, contains...

